Tech Company Financing Transactions
Vita Therapeutics Funding Round
Vita Therapeutics closed a $32 million Series A funding round on 6/24/2021. Investors included Cambrian Biopharma, Early Light Ventures and Kiwoom Bio.
Transaction Overview
Company Name
Announced On
6/24/2021
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series A
Investors
Proceeds Purpose
This funding will support the manufacturing of cells needed for clinical evaluation as well as patient recruitment efforts for the first clinical trial.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1209 Orange St.
Wilmington, DE 19801
USA
Wilmington, DE 19801
USA
Phone
Undisclosed
Website
Email Address
Overview
Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Douglas Falk
Co-Founder
Peter Andersen
VP - Regulatory Affairs
Steven Brooks
Browse more venture capital transactions:
Prev: 6/24/2021: Strand Therapeutics venture capital transaction
Next: 6/24/2021: Moderne venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs